PROGRESSIVE CARE INC - RXMD STOCK NEWS

Progressive Care Inc. (OTCQB: RXMD) has expanded its corporate services to offer COVID-19 testing and vaccination management through its PharmcoRx.com platform. Businesses can now schedule tests online, choose locations, and receive results in 15-30 minutes. In 2021, the company generated over $4 million in testing revenue and operates over 40 rapid PCR test analyzers. CEO Alan Jay Weisberg highlighted the company's commitment to enhancing its digital platform despite challenges from COVID-19 variants.

Progressive Care Inc. (OTCQB: RXMD) filed a Form 10 with the SEC to register its common stock under Section 12(g) of the Exchange Act. This filing will take effect on April 11, 2022, unless withdrawn. Following effectiveness, the Company will be required to submit annual, quarterly, and current reports, enhancing its transparency. CEO Alan Jay Weisberg expressed that this step aligns with their goal to become a fully reporting company, which may increase shareholder value as they aim for a Nasdaq listing.

Progressive Care Inc. (OTCQB: RXMD) announced that its subsidiary, PharmcoRx, has been approved as one of 35 COVID-19 test vendors for U.S. travelers to China during the Beijing Winter Olympics. This recognition highlights the company's commitment to quality service and accuracy in COVID-19 testing. CEO Alan Jay Weisberg emphasized that their selection was based on their timeliness and service quality. This development could enhance the company's visibility and revenue potential as travel resumes and testing remains crucial.

Progressive Care, Inc. (OTCQB: RXMD) reported significant growth in COVID-19 testing revenue for Q4 and the entire year 2021, increasing 132% to $1.4 million and 620% to $4.3 million, respectively. CEO Alan Jay Weisberg highlighted the company's aggressive expansion strategy as a key driver of this success. The company operates over 40 COVID-19 Rapid PCR Test analyzers, capable of testing up to 1,000 patients daily. Its services include rapid detection tests and antibody testing, reinforcing its position as a trusted healthcare provider in Florida.

Progressive Care (OTCQB:RXMD) has announced a strategic partnership with Aimpoint Digital to enhance their analytics capabilities utilizing Alteryx's platform. This collaboration aims to streamline data management and improve efficiency, allowing the company to handle large datasets effectively. Key benefits include a reported 35% improvement in database run-time for pharmacy data reporting and better insights into prescription delivery processes. The partnership is expected to significantly optimize operations and automate internal processes across the organization.

Progressive Care Inc. (OTCQB: RXMD) has announced the implementation of Podium, a two-way communication platform aimed at enhancing patient engagement and operational efficiency. The new system will allow for improved internal performance metrics, customer satisfaction ratings, and streamlined patient communication. podiatrists can now connect with over 100 pharmacy technicians, significantly reducing wait times for prescription issues and COVID-19 testing queries. This integration is expected to bolster local SEO and enhance marketing efforts across various online platforms.

Progressive Care Inc. (OTCQB: RXMD) announced a settlement agreement with investors Chicago Venture Partners and Iliad Research and Trading, effective January 20, 2022. The agreement resolves claims and includes a $175,000 payment from CVP to Progressive Care, terminating prior agreements. Iliad will not sell shares during a standstill period and is subject to penalties for non-compliance. The Iliad Note's maturity date has been extended to April 15, 2022, with the option to further extend to May 15, 2022, at an increased balance. Key financial terms have been slightly modified.

Progressive Care Inc. (OTCQB: RXMD) has appointed Birute Norkute and Joseph Ziegler to its Board of Directors. CEO Alan Jay Weisberg expressed optimism about their contributions, emphasizing Ziegler's expertise in healthcare finance and Norkute's operational leadership in the company. Ziegler has a proven track record in driving growth within healthcare organizations, while Norkute has been instrumental in enhancing medication adherence and operational efficiency at Progressive Care.

Progressive Care Inc. held a Special Meeting on December 3, 2021, where stockholders approved three major proposals. Proposal 1 allows for a reverse stock split between 1-for-10 and 1-for-250, aimed at better positioning the company for Nasdaq listing. Proposal 2 reduces authorized common stock from 1 billion to 100 million shares, contingent on Proposal 1's approval. Proposal 3 permits adjournment to solicit further votes if needed. CEO Alan Jay Weisberg emphasized shareholder trust in the company’s future and commitment to enhancing shareholder value.